Search

Displaying results 3811 - 3820 of 8010 in total
  1. Drug

    AAV8-RK-RetGC

    go.drugbank.com/drugs/DB32389
    Experimental

    AAV8-RK-RetGC is an adeno-associated virus (AAV) viral vector platform with a serotype 8 capsid with a complementary DNA (cDNA) of the human GUCY2D gene encoding RetGC.

    Synonyms: AAV8-RK-RetGC
  2. Drug

    Biomed 101

    go.drugbank.com/drugs/DB05851
    Investigational

    Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. … Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.

  3. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)

  4. Drug

    Chromic nitrate

    go.drugbank.com/drugs/DB14527
    Approved

  5. Drug

    Rauwolfia serpentina root

    go.drugbank.com/drugs/DB09363
    Investigational

    This product was approved prior to Jan 1, 1982, but since, has been discontinued due to its propensity for leading to depression [L1616, L1630]. … For this reason, various studies into biotechnological applications of this plant have been performed.

  6. Drug

    Pramiracetam

    go.drugbank.com/drugs/DB13247
    Approved

    Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression [L5470].

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  7. Drug

    Tasimelteon

    go.drugbank.com/drugs/DB09071
    ApprovedInvestigational

    Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010. … Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD).

  8. Drug

    Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15740
    Investigational

    In humans, OM-MSCs are derived from the olfactory mucosa which is collected in vivo through rhinoscopy techniques and nasal forceps. … OM-MSCs are also immunomodulatory and have potential for treating immunological diseases.

  9. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    [A262561] Nirogacestat was approved under the brand name OGSIVEO on November 27, 2023, by the FDA for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. … Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors.

  10. Drug

    Relutrigine

    go.drugbank.com/drugs/DB21614
    Investigational

    Relutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).